Inhibikase Therapeutics, Inc.
For the period ended Mar 31, 2025. Filed May 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 14, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| Incorporated by Reference to SEC Filing | |||||
|---|---|---|---|---|---|
| ExhibitNo. | Filed Exhibit Description | Form | ExhibitNo. | File No. | Date Filed |
| 2.1†^ | Agreement and Plan of Merger and Reorganization, dated February 21, 2025, by and among Inhibikase Therapeutics, Inc., Project IKT Merger Sub, Inc., CorHepta Pharmaceuticals, Inc. and Sellers’ Representative | 10-K | 2.1 | 001-39676 | 03/27/2025 |
| 3.1 | Amended and Restated Certificate of Incorporation of Inhibikase Therapeutics, Inc. | 8-K | 3.1 | 001-39676 | 12/29/2020 |
| 3.2 | Certificate of Amendment to Amended and Restated Certificate of Incorporation of Inhibikase Therapeutics, Inc. | 8-K | 3.1 | 001-39676 | 06/29/2023 |
| 3.3 | Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Inhibikase Therapeutics, Inc. | 8-K | 3.1 | 000-39676 | 01/06/2025 |
| 3.4 | Amended and Restated Bylaws of Inhibikase Therapeutics, Inc. | 8-K | 3.3 | 001-39676 | 12/29/2020 |
| 4.1 | Specimen common stock certificate of the Registrant | S-1 | 4.1 | 333-240036 | 07/23/2020 |
| 10.1 | Consulting Agreement, by and between Inhibikase Therapeutics, Inc. and Milton H. Werner, dated February 13, 2025 | 10-K | 10.27 | 001-39676 | 03/27/2025 |
| 10.2# | Employment Agreement, by and between Inhibikase Therapeutics, Inc. and Mark Iwicki, dated February 14, 2025 | 10-K | 10.28 | 001-39676 | 03/27/2025 |
| 10.3# | Employment Agreement, by and between Inhibikase Therapeutics, Inc. and Christopher Cabell, dated February 21, 2025 | 10-K | 10.29 | 001-39676 | 03/27/2025 |
| 10.4# | Employment Agreement, by and between Inhibikase Therapeutics, Inc. and David McIntyre, dated as of March 13, 2025 | 8-K | 99.2 | 001-39676 | 04/14/2025 |
| 31.1* | Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | ||||
| 31.2* | Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | ||||
| 32.1** | Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | ||||
| 32.2** | Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | ||||
| 101.INS | Inline XBRL Instance Document | ||||
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | ||||
| 104 | Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101) | ||||
(#) A contract, compensatory plan or arrangement to which a director or executive officer is a party or in which one or more directors or executive officers are eligible to participate.
(*) Filed herewith.
(†) Annexes, schedules and/or exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company agrees to furnish supplementally a copy of any omitted attachment to the SEC on a confidential basis upon request.
(^) Portions of this exhibit (indicated by asterisks) have been omitted in accordance with Item 601(b)(10) of Regulation S-K.
(**) Exhibits 32.1 and 32.2 are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall such exhibits be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act or the Exchange Act, except as otherwise stated in any such filing.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.